TY - JOUR
T1 - Circulating biomarkers predictive of tumor response to cancer immunotherapy
AU - Lee, Ernest Y.
AU - Kulkarni, Rajan P.
N1 - Funding Information:
E.Y.L. acknowledges support from the UCLA-Caltech Medical Scientist Training Program (T32GM008042), the Dermatology Scientist Training Program (T32AR071307) at UCLA, and an Early Career Research Grant from the National Psoriasis Foundation. R.P.K. acknowledges support from the OHSU Physician-Scientist Award, the Department of Defense (W81XWH-17-1-0098 and W81XWH-17-1-0514), Cancer Research Institute, LUNGevity, and Melanoma Research Alliance. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/10/3
Y1 - 2019/10/3
N2 - Introduction: The advent of checkpoint blockade immunotherapy has revolutionized cancer treatment, but clinical response to immunotherapies is highly heterogeneous among individual patients and between cancer types. This represents a challenge to oncologists when choosing specific immunotherapies for personalized medicine. Thus, biomarkers that can predict tumor responsiveness to immunotherapies before and during treatment are invaluable. Areas covered: We review the latest advances in 'liquid biopsy' biomarkers for noninvasive prediction and in-treatment monitoring of tumor response to immunotherapy, focusing primarily on melanoma and non-small cell lung cancer. We concentrate on high-quality studies published within the last five years on checkpoint blockade immunotherapies, and highlight significant breakthroughs, identify key areas for improvement, and provide recommendations for how these diagnostic tools can be translated into clinical practice. Expert opinion: The first biomarkers proposed to predict tumor response to immunotherapy were based on PD1/PDL1 expression, but their predictive value is limited to specific cancers or patient populations. Recent advances in single-cell molecular profiling of circulating tumor cells and host cells using next-generation sequencing has dramatically expanded the pool of potentially useful predictive biomarkers. As immunotherapy moves toward personalized medicine, a composite panel of both genomic and proteomic biomarkers will have enormous utility in therapeutic decision-making.
AB - Introduction: The advent of checkpoint blockade immunotherapy has revolutionized cancer treatment, but clinical response to immunotherapies is highly heterogeneous among individual patients and between cancer types. This represents a challenge to oncologists when choosing specific immunotherapies for personalized medicine. Thus, biomarkers that can predict tumor responsiveness to immunotherapies before and during treatment are invaluable. Areas covered: We review the latest advances in 'liquid biopsy' biomarkers for noninvasive prediction and in-treatment monitoring of tumor response to immunotherapy, focusing primarily on melanoma and non-small cell lung cancer. We concentrate on high-quality studies published within the last five years on checkpoint blockade immunotherapies, and highlight significant breakthroughs, identify key areas for improvement, and provide recommendations for how these diagnostic tools can be translated into clinical practice. Expert opinion: The first biomarkers proposed to predict tumor response to immunotherapy were based on PD1/PDL1 expression, but their predictive value is limited to specific cancers or patient populations. Recent advances in single-cell molecular profiling of circulating tumor cells and host cells using next-generation sequencing has dramatically expanded the pool of potentially useful predictive biomarkers. As immunotherapy moves toward personalized medicine, a composite panel of both genomic and proteomic biomarkers will have enormous utility in therapeutic decision-making.
KW - Checkpoint blockade immunotherapy
KW - circulating tumor cells
KW - liquid biopsy
KW - noninvasive diagnostics
KW - personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=85072588375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072588375&partnerID=8YFLogxK
U2 - 10.1080/14737159.2019.1659728
DO - 10.1080/14737159.2019.1659728
M3 - Review article
C2 - 31469965
AN - SCOPUS:85072588375
VL - 19
SP - 895
EP - 904
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 10
ER -